NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Pasithea Therapeutics Corp. (KTTA) Stock Analysis

Pasithea Therapeutics Corp. (KTTA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

KTTA

$0.58

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KTTA with… →

KTTA Key Statistics

As of Sep 4, 2026
Trading
Open
$0.58
Previous Close
$0.58
Day's Range
0.57–0.59
52-Week Range
0.28–2.06
Volume
222.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.33
Valuation
Market Cap
$19.38M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.35
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$20.43M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
33.41M
1-Year Return
−27.14%
Dividend and dates
Avg Volume
712.54K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KTTA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−55.04%
2025−59.05%
2024−57.43%
2023−42.37%
2022−63.73%
2021 (partial year)−50.28%

As of September 4, 2026.

KTTA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$20.43M—
2024$0.00−$13.90M—
2023$0.00−$15.96M—
2022$0.00−$13.94M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$20.86M−$20.43M—
2024$0.00—−$14.25M−$13.90M—
2023$0.00—−$15.98M−$15.96M—
2022$0.00$373.36K−$12.59M−$13.94M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KTTA Valuation vs Biotechnology Median

Median of 656 stocks
MetricKTTABiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Pasithea Therapeutics Corp. (KTTA) at $19.38M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 5 employees.

KTTA last closed at $0.58 on September 4, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $0.28 to $2.06. The latest close sits 106.41% above that 52-week low.

Financial Health

In fiscal 2025, Pasithea Therapeutics Corp. reported revenue of $0.00. The same year closed with a net loss of $20.43M. The reported profit margin is 0%. Trailing earnings per share are −1.35.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is −27.14%. Measured over 5 years, that is −61.79% a year compounded. The reported beta is 0.33. Annualized volatility over the trailing 5 years is 132.17%.

Growth & Income

The record shows no dividend for KTTA.

Across the complete calendar years on file, 2023 returned −42.37% and 2022 returned −63.73%. Of the 4 complete calendar years on file, 0 finished higher. 2026 is still running; the price is −55.04% year to date.

Peer Comparison

Pasithea Therapeutics Corp. (KTTA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Pasithea Therapeutics Corp. KTTA $19.38M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Pasithea Therapeutics Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Visit website →